



Acquisition of Preventice Solutions
January 21, 2021

Financial disclaimers

Safe harbor for forward-looking statements:

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, the closing of the acquisition, product development and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings "Risk Factors" and "Safe Harbor for Forward-Looking Statements." Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Market Estimates:

Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

Non-GAAP Financial Measures:

This presentation contains non-GAAP measures (denoted with *) in talking about our company's performance. The reconciliations of those non-GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to the end of this presentation.

BSX and Preventice Solutions: Leadership across continuum of care

➤ Worldwide leader in Cardiac Rhythm Management and Electrophysiology

➤ Lux-Dx™ insertable cardiac monitor (ICM) for long-term arrhythmia monitoring

➤ HeartLogic™: First FDA-approved alert for CRM Heart Failure Diagnosis

➤ Deep R&D and clinical expertise

COMPLETE PORTFOLIO & COMMERCIAL SCALE

**All 5 diagnostic modalities +
multiple therapeutic options**

➤ Leader in digital health with solutions for every segment of wearable cardiac diagnostics

➤ Demonstrated sales execution and expertise in cardiac diagnostics

➤ Advanced artificial intelligence platform

➤ Remote rhythm monitoring services and Independent Diagnostic Testing Facility (IDTF) capabilities

BSX to acquire Preventice Solutions



Preventice Overview

- Ambulatory ECG (AECG) devices and monitoring services
 - Identifying and managing heart rhythm disorders for millions of patients
- Privately held company founded in 2014
- ~1000 employees with facilities in CA, TX, MN, ND

Deal Terms

- BSC has held a strategic investment since 2015
- Price (net of existing ownership): ~\$720M up-front and up to ~\$230M in potential commercial milestone payments
- Expected to close H1:2021, subject to customary conditions



Shareholder Value

- Immediately accretive to top-line growth: \$158M net sales in 2020, +30% YoY growth
- Attractive ROIC expected by year 5
- Estimated adjusted EPS* impact:
 - Immaterial 2021, accretive by at least \$0.01 in 2022, and increasingly accretive thereafter

Market and portfolio overview




US Cardiac Diagnostic Market



BSX + Preventice: Only company to offer full spectrum of cardiac diagnostic solutions to meet the needs of patients and providers


Preventice key products & solutions



BodyGuardian®
MINI PLUS



Broad suite of remote monitoring capabilities led by sophisticated 4-in-1 ambulatory cardiac monitoring technology



BeatLogic®



Seamless integration of artificial and human intelligence enabling enhanced physician efficiency and experience



PatientCare



Fully-Integrated cloud-based platform driving near real-time analysis of AECG data for improved clinical diagnosis and outcomes

Preventice competitive strengths



PatientCare provides transparency, flexibility and near real-time analysis



Increased flexibility and convenience with BodyGuardian MINI Plus 4-in-1



High degree of patient comfort leading to increased compliance



Highly accurate analysis and reporting powered by sophisticated BeatLogic deep learning networks and artificial intelligence



Flexible service model customized for the needs of each physician practice



Enhanced workflows via customized EMR integration

Growth accretive and meaningful strategic synergies

Category Leadership

Further category leadership strategy in cardiac diagnostics and services

- AECG complementary to existing BSX diagnostics portfolio
 - Unique positioning across continuum of care: all 4 AECG testing modalities + ICM + HeartLogic + CRM + EP
- Continued strong share growth in long-term Holter segment

Attractive Market

Growth accretive; diversifies Rhythm Management into high-growth adjacency

- ~\$1.8B U.S. market (ICM + AECG) growing double-digits
- Growing prevalence of arrhythmias; 50M+ people affected by arrhythmias globally
- Potential TAM expansion; 10M+ patients with asymptomatic atrial fibrillation in the US

New Capabilities

Adds new commercial, technical and service capabilities

- Immediate call point expansion with two sales teams
- Opportunity for digital health innovation with AI expertise
- IDTF has potential expansion beyond cardiac arrhythmias